Boylan et al. 2017 [48], in their study on 81 women (healthy controls, benign disease, early and late stage serous ovarian cancer), were able to increase sensitivity for the detection of early stage serous cancer versus healthy women from 0.93 (CA125 alone) to 0.95 (specificity 0.95) with a 12-protein classifier derived from analysis of the Olink’s Oncology Iv2 panel of 92 proteins (CA125, CD40.L, CD69, CXCL9, CXCL13, EGFR, EpCAM, DJ-1(PARK7), SELE, LAP.TGF.beta.1, TF, and VEGFR2) [48]. The gene discussed is TF; the disease is ovarian serous adenocarcinoma.